A new antivenom relies on antibodies from the blood of Tim Friede, who immunized himself against snakebites by injecting increasing doses of venom into his body.

The firm is expecting Phase III readouts this year for its FGFR2b drug bemarituzumab and is advancing a second KRAS inhibitor to the clinic.